Page 17 - சந்தைப்படுத்தல் அங்கீகாரம் வைத்திருப்பவர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Apr 5, 2021 12:23pm Chime Biologics second biologics site, pictured above, will lift total manufacturing capacity to 140,000 liters, the CDMO said.(PR Newswire/Chime Biologics) After locking up a $125 million Series A in early 2020, China-based CDMO Chime Biologics has raised another $65 million to help build and kit out a second plant in Wuhan, China.  The $190 million investment will fuel an expansion over the next five years at its site in Wuhan, taking capacity there to 140,000 liters. The new plant will join Chime s first facility there, which is built around a modular manufacturing system from Cytiva Life Sciences. Chime counts monoclonal and bispecific antibodies, fusion and conjugated proteins, and enzymes among its manufacturing repertoire, according to the company’s website.

Cytiva life sciencesFidelity internationalCytiva lifeWuhan east lake high techMarketing authorization holderFierce pharmaPanacea ventureWuxi bioWuxi biologicsGe healthcareChime biologicsBiologics plantDrug manufacturingManufacturing plantManufacturing expansionநம்பகத்தன்மை சர்வதேச